Crohn's disease

Lore & Background

Oppenheimer at Mount Sinai Hospital in New York, described a series of people with inflammation of the terminal ileum of the small intestine. The decision to name the disease after Crohn remains controversial, as the disease had previously been described more than once. While Crohn, in his memoir, describes his original investigation of the disease, Ginzburg provided strong evidence of how he and Oppenheimer were the first to study the disease. The disease affects about 3.2 per 1,000 people in Europe and North America, and is less common in Asia and Africa. It has historically been more common in the developed world, but rates have been increasing, particularly in the developing world, since the 1970s. Onset tends to start in adolescence and young adulthood, though it can occur at any age, and males and females are affected roughly equally. Although the precise causes of Crohn's disease are unknown, it is believed to be caused by a combination of environmental, immune, and bacterial factors in genetically susceptible individuals. About half of the overall risk is related to genetics, with more than 70 genes involved. Tobacco smokers are about 1.5 to 2 times as likely to develop Crohn's disease as non-smokers, and the disease is often triggered after a gastroenteritis episode.

Reader's Guide

Crohn's disease is a significant chronic inflammatory bowel disease with no known cure, affecting millions worldwide. Its naming after Burrill Bernard Crohn remains controversial due to prior descriptions by others, including Ginzburg and Oppenheimer. The disease's impact is substantial: one in five people with the disease is admitted to the hospital each year, and half will require surgery within ten years. It is associated with a slightly reduced life expectancy and increased risk of colorectal and small bowel cancer. Treatment focuses on symptom management, remission maintenance, and relapse prevention, with corticosteroids, methotrexate, or thiopurines used, and smoking cessation recommended. The disease's increasing rates in the developing world since the 1970s highlight its evolving epidemiology. Understanding its complex interplay of genetic, environmental, immune, and bacterial factors remains a key area of research, as does the exact underlying immune problem, which may be immunodeficiency rather than autoimmunity.

Did You Know?

• Tobacco smokers are about 1.5 to 2 times as likely to develop Crohn's disease as non-smokers.
• About half of the overall risk for Crohn's disease is related to genetics, with more than 70 genes involved.
• One in five people with Crohn's disease is admitted to the hospital each year, and about 20-30% will require surgery within ten years—a rate that has declined thanks to modern treatments.
• Crohn's disease affects about 3.2 per 1,000 people in Europe and North America, and rates have been increasing in the developing world since the 1970s.

Origins & Naming

The disease bears the name of gastroenterologist Burrill Bernard Crohn, but the story behind that naming is far from straightforward. In 1932, Crohn, alongside colleagues Leon Ginzburg and Gordon D. Oppenheimer at Mount Sinai Hospital in New York, published a description of patients showing inflammation in the terminal ileum, the segment of small intestine most frequently struck by the condition. Yet the disease had been documented before their work, and the decision to attach Crohn's name to it has remained a point of contention. In his own memoir, Crohn recounts his initial investigation, but Ginzburg later presented compelling evidence that he and Oppenheimer had been studying the condition first. The naming controversy thus sits alongside the medical history itself, a reminder that even the labels we use to define a condition carry their own disputes and politics.

The Body's Betrayal: Symptoms & Manifestations

Crohn's disease can strike virtually any segment of the gastrointestinal tract, and its symptoms reflect that wide reach. Abdominal pain, often localized to the lower right, frequently appears first, accompanied by diarrhea that may range from watery and high-volume in ileitis to smaller in quantity but more frequent in colitis. In severe cases, a person may experience more than twenty bowel movements a day and be roused from sleep to go. Beyond the gut, the disease can trigger anemia, joint inflammation, eye inflammation, fatigue, and distinctive skin conditions such as pyoderma gangrenosum or erythema nodosum. Perianal complications including fissures, fistulae, and abscesses are also prominent. Upper gastrointestinal involvement, once thought rare, is now recognized in roughly thirteen to sixteen percent of cases, presenting with difficulty swallowing, painful swallowing, and vomiting. Even the mouth may be affected by recurrent canker sores, though it remains unclear whether these are truly disease-related or simply common in the general population.

Roots & Risk: What Drives the Disease

No single cause explains Crohn's disease. Current understanding points to a convergence of genetic susceptibility, environmental exposures, immune dysregulation, and bacterial factors. Roughly half of a person's overall risk is tied to genetics, with more than seventy genes implicated. The immune system appears to mount a chronic inflammatory defense against the gut, possibly targeting microbial antigens, yet the condition does not behave like a classic autoimmune disorder in which the body attacks itself. Smoking stands out as a major modifiable risk: tobacco users face roughly three times the likelihood of developing the disease compared to non-smokers. A prior episode of gastroenteritis can serve as a trigger. Geographically, Crohn's disease has historically been more prevalent in Europe and North America, at about 3.2 per 1,000 people, than in Asia and Africa, though rates in the developing world have been climbing since the 1970s. Onset typically falls in adolescence and young adulthood, though it can emerge at any age, and males and females are affected in roughly equal numbers.

Living With It: Treatment & Prognosis

There is no known cure for Crohn's disease, and management centers on easing symptoms, sustaining remission, and preventing relapse. For newly diagnosed patients, a short course of corticosteroids may be prescribed to bring rapid relief, paired with a maintenance medication such as methotrexate or a thiopurine to guard against recurrence. Smoking cessation is strongly urged, given its role in worsening the condition. The disease carries significant long-term burdens: one in five patients is hospitalized each year, and half will need surgery within a decade. Surgeons aim to remove as little tissue as possible, yet intervention becomes essential for abscesses, certain obstructions, and cancers. The risk of colorectal and small bowel cancer is markedly elevated, prompting colonoscopic surveillance every one to three years beginning eight years after diagnosis. In 2015, inflammatory bowel disease as a whole accounted for 47,400 deaths worldwide, and those living with Crohn's face a slightly reduced life expectancy.